- Home
- SWI vs BLTE Comparison
SWI vs BLTE Comparison
Compare SWI & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWI
- BLTE
- Stock Information
- Founded
- SWI 1999
- BLTE 2018
- Country
- SWI United States
- BLTE United States
- Employees
- SWI N/A
- BLTE N/A
- Industry
- SWI Computer Software: Prepackaged Software
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- SWI Technology
- BLTE Health Care
- Exchange
- SWI Nasdaq
- BLTE Nasdaq
- Market Cap
- SWI 2.4B
- BLTE 2.1B
- IPO Year
- SWI 2009
- BLTE 2022
- Fundamental
- Price
- SWI $14.62
- BLTE $58.91
- Analyst Decision
- SWI Hold
- BLTE Strong Buy
- Analyst Count
- SWI 7
- BLTE 4
- Target Price
- SWI $15.14
- BLTE $96.33
- AVG Volume (30 Days)
- SWI 432.4K
- BLTE 46.8K
- Earning Date
- SWI 02-06-2025
- BLTE 03-10-2025
- Dividend Yield
- SWI N/A
- BLTE N/A
- EPS Growth
- SWI N/A
- BLTE N/A
- EPS
- SWI 0.22
- BLTE N/A
- Revenue
- SWI $784,725,000.00
- BLTE N/A
- Revenue This Year
- SWI $5.08
- BLTE N/A
- Revenue Next Year
- SWI $3.04
- BLTE N/A
- P/E Ratio
- SWI $65.39
- BLTE N/A
- Revenue Growth
- SWI 4.96
- BLTE N/A
- 52 Week Low
- SWI $10.14
- BLTE $31.01
- 52 Week High
- SWI $14.94
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- SWI 62.24
- BLTE 46.75
- Support Level
- SWI $13.53
- BLTE $52.03
- Resistance Level
- SWI $14.20
- BLTE $61.66
- Average True Range (ATR)
- SWI 0.26
- BLTE 3.51
- MACD
- SWI 0.02
- BLTE 0.25
- Stochastic Oscillator
- SWI 99.54
- BLTE 42.55
About SWI SolarWinds Corporation
SolarWinds Corp is a provider of information technology (IT), and management software. Company offers full-stack observability solutions. The company's business is focused on building products that enable technology professionals and leaders to securely monitor and manage the performance of their IT environments, whether on-premises, in the cloud or in hybrid deployments. The products offered are designed to monitor and manage networks, systems, databases and applications across on-premises, multi-cloud and hybrid IT environments without the need for customization or professional services.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.